Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

This study is testing teplizumab — an immune-modifying drug already approved in the US to delay the development of type 1 diabetes — specifically in Japanese patients. Type 1 diabetes happens when the immune system attacks the insulin-producing cells in the pancreas. This trial is for people who are at high risk of developing type 1 diabetes but do not have it yet (Stage 2 — meaning abnormal blood sugar with multiple autoantibodies present). **You may be eligible if...** - You are between 8 and 34 years old (inclusive) - You were born in Japan or are of Japanese descent with all four grandparents born in Japan - You have tested positive for at least 2 type 1 diabetes-related autoantibodies (proteins that suggest the immune system is attacking the pancreas) - You have abnormal results on a blood sugar test confirming Stage 2 type 1 diabetes (pre-symptomatic) **You may NOT be eligible if...** - You already have clinical (symptomatic) type 1 diabetes (Stage 3) - You are not of Japanese descent as defined by the study criteria - You are under 8 or over 34 years old - You do not have at least 2 relevant autoantibodies Talk to your doctor to see if this trial is right for you.